{'fraction_non_alphanumeric': 0.04319654427645788, 'fraction_numerical': 0.0367170626349892, 'mean_word_length': 4.728395061728395, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A new ultra-low-dose combination oral contraceptive.

Data were compiled from 17 U.S. sites during a study of levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg. A total of 1,130 women participated in 11,604 cycles of treatment. Efficacy, cycle characteristics, bleeding irregularities and side effects were studied. Weight and blood pressure means were analyzed with the paired t-test. Subject acceptance of this new combination oral contraceptive was high.